Slides
Page 1
Presentation Quarter 3, 2026 October 22, 2026
Page 2
Ulrika Kolsrud President and CEO
Page 3
Organic sales growth EBITA excl. IAC EBITA margin excl. IAC Operating cash flow -0.3% SEK 4,725m 13.1% SEK 5,783m Resilient performance in a challenging market Ongoing price adjustments, sequentially higher prices Saving programs delivering Acquisition of feminine care business in Brazil Consumer Tissue strategic review proceeding according to plan Highlights Q3 2026
Page 4
Health & Medical Q3 2026 Higher prices and stable volumes Growth in both Incontinence Products and Medical Solutions Expanded compression garment offering with JOBST® Elvarex® Soft Ready-to-Wear
Page 5
Personal Care Q3 2026 Strong volume-driven growth in Incontinence Products and Feminine Care Market share gains for branded sales across categories Continued roll-out of SmartProtect technology High growth in North America and Latin America
Page 6
Acquisition strengthening Essity’s feminine care position in Latin America Acquiring the market leading brand Carefree, Sempre Livre and o.b. in Brazil Approx. SEK 1.4bn1) in net sales, with good profitability Purchase price of USD 284m, expected closing in Q2 2027 Supports the strategy to grow in Essity’s most value-creating categories in attractive markets 1) BRL 800m; for the twelve-month period ending June 30, 2026
Page 7
High activity in Personal Care North America Integrating Feminine Care acquisition in North America Implementing new go to market in US TENA online market share in US continuing to grow
Page 8
Consumer Tissue Q3 2026 Sales decline driven by volume and price Manufacturing footprint optimization in Latin America Margins impacted by previous price reductions and increased cost headwinds Ongoing price adjustments, with sequentially higher prices
Page 9
Professional Hygiene Q3 2026 Continued growth of premium products Lower volumes driven by base assortment Tork Vision Cleaning gaining traction across the globe
Page 10
Fredrik Rystedt Executive Vice President and CFO
Page 11
Health & Medical • Incontinence Health Care • Medical Solutions Personal Care • Incontinence Retail • Feminine Care • Baby Care Consumer Tissue Professional Hygiene Organic sales growth: +1.2% +1.5% +0.7% +3.2% +5.1% +5.6% -3.9% -3.0% -1.1% -0.3% Net sales Q3 2025 Net sales Q3 2026 Currency SEK 34.6bn -0.1% -0.2% +1.9% SEK 36.1bn Sales growth: +4.1% Organic sales growth: -0.3% Volume Acquisition +2.5% Price/mix Stable volumes and positive impact from acquisition
Page 12
Health & Medical Personal Care Consumer Tissue Professional Hygiene 18.4% 13.5% 8.6% 17.0% EBITA margin excl. IAC:13.1% EBITA margin excl. IAC Q3 2025 Impact Gross Profit Margin A&P 14.6% -170bps 0bps +20bps 13.1% SG&A (excl. A&P) Savings SEK ~150m EBITA margin excl. IAC Q3 2026 Resilient EBITA margin excl. IAC Savings SEK ~180m
Page 13
Items affecting comparability Restructuring costs SEK ~450m SG&A savings program Restructuring costs SEK ~500m Consumer Tissue manufacturing footprint optimization in Latin America Other, including M&A costs SEK ~140m Total IAC Q3 SEK 1 089m
Page 14
Strong operating cash flow 6.5 3.3 3.8 1.5 5.3 4.4 4.4 2.8 5.8 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 SEKbn
Page 15
Strong balance sheet 30.8 26.5 25.0 1.2 1.0 1.0 0 0,5 1 1,5 2 2,5 3 3,5 4 4,5 5 1 6 11 16 21 26 31 36 2024 2025 9M 2026 Net Debt, SEKbn Net Debt / EBITDA excl. IAC SEKbn + Cash flow + IFRS revaluation of pension assets and obligations - Acquisition - Dividends and share buybacks - Other, including currency
Page 16
Ulrika Kolsrud President and CEO
Page 17
Summary Q3 2026 – stable volumes, resilient profitability and strong cash flow Priorities: Compensate higher input costs with price, while growing market shares Successful execution of initiatives - SG&A and COGS saving programs - Integration of Feminine Care acquisitions - Consumer Tissue strategic review Drive further actions to accelerate profitable growth
Page 18
This presentation may contain forward-looking statements. Such statements are based on our current expectations and are subject to certain risks and uncertainties that could negatively affect our business. Please read our most recent annual report for a better understanding of these risks and uncertainties.
Page 19
Q&A
Page 20
Sandra Åberg Vice President Investor Relations sandra.aberg@essity.com +46 70 564 96 89 Investor Relations Viveca Dominguez Director Investor Relations viveca.dominguez@essity.com +46 70 278 51 52 Janet Östergren Investor Relations Officer janet.ostergren@essity.com +46 70 310 13 74 Contacts